Session On: Cardiovascular Biomarkers Allied Academies Conferences

Session On: Cardiovascular Biomarkers

ic or predictive types. Many of these biomarkers have been vigorously tested to assess their clinical utility across different patients with atherosclerotic CVD. The desirable characteristics of any cardiovascular biomarker includes measurement should be easy, preferably at point-of-care over a short period of time with adequate precision and accuracy. These biomarkers can reflect pathophysiologic process of cardiovascular diseases, and also may be able to give information about prognosis and assist guide clinical decision making without duplicating any information that is already available clinically.

Biomarkers evaluating prognostic outcomes should report discrimination, calibration and reclassification in patients by evaluating statistical models with and without the biomarker in order to demonstrate their added value over traditional and other commonly used biomarkers. Genetic biomarkers are at the forefront of being evaluated for added utility and they too need rigorous assessments to evaluate their relations with the CVD and for their added advantage over traditional risk factors. Utilizing biomarkers as surrogate end points for predictive and prognostic values in clinical trials will likely dictate our future of CVD treatment, and will also open up avenues to evaluate biomarkers as possible targets for drug delivery and development.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK